CaldarolaG, PirroF, di StefaniA, et al.Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther, 2020; 20(6):665–672 Available at: https://pubmed.ncbi.nlm.nih.gov/32045273/. Accessed April12, 2022.
2.
TodbergT, ZachariaeC, KrustrupD, et al.The effect of treatment with anti–interleukin-17 in patients with allergic contact dermatitis. Contact Dermatitis, 2018; 78(6):431–432 Available at: https://pubmed.ncbi.nlm.nih.gov/29722024/. Accessed April12, 2022.
3.
MuftiA, LuJD, SachdevaM, et al.Patch testing during immunosuppressive therapy: a systematic review. Dermatitis, 2021; 32(6):365–374 Available at: https://pubmed.ncbi.nlm.nih.gov/33896928/. Accessed April12, 2022.
4.
Magdaleno-TapialJ, Valenzuela-OñateC, Ortiz-SalvadorJM, et al.Contact allergy to isothiazolinones epidemic: current situation. Contact Dermatitis, 2020; 82(2):83–86 Available at: https://pubmed.ncbi.nlm.nih.gov/31515812/. Accessed April12, 2022.
5.
SilverbergJI, HouA, DeKovenJG, et al.Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: North American Contact Dermatitis Group data, 2001–2016. Contact Dermatitis, 2021; 85(4):435–445 Available at: https://pubmed.ncbi.nlm.nih.gov/33931870/. Accessed April12, 2022.
